Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) – SVB Leerink dropped their Q1 2022 EPS estimates for Lantheus in a report released on Tuesday, April 12th. SVB Leerink analyst D. Antalffy now anticipates that the medical equipment provider will post earnings per share of $0.40 for the quarter, down from their prior forecast of $0.45. SVB Leerink currently has a “Outperform” rating and a $75.00 price target on the stock. SVB Leerink also issued estimates for Lantheus’ Q2 2022 earnings at $0.44 EPS, Q3 2022 earnings at $0.45 EPS, Q4 2022 earnings at $0.52 EPS, FY2022 earnings at $1.83 EPS and FY2023 earnings at $2.20 EPS.
Several other research analysts also recently commented on LNTH. StockNews.com began coverage on shares of Lantheus in a report on Thursday, March 31st. They issued a “hold” rating on the stock. Zacks Investment Research upgraded shares of Lantheus from a “sell” rating to a “buy” rating and set a $32.00 price target on the stock in a research report on Thursday, February 24th. Finally, Truist Financial started coverage on shares of Lantheus in a research report on Tuesday. They set a “buy” rating and a $77.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $51.00.
Lantheus (NASDAQ:LNTH – Get Rating) last announced its quarterly earnings results on Thursday, February 24th. The medical equipment provider reported $0.25 EPS for the quarter, beating the consensus estimate of $0.17 by $0.08. The company had revenue of $129.60 million for the quarter, compared to analyst estimates of $111.77 million. Lantheus had a negative net margin of 16.76% and a positive return on equity of 6.80%. Lantheus’s revenue was up 37.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.07 earnings per share.
In other news, CFO Robert J. Jr. Marshall sold 8,851 shares of the company’s stock in a transaction dated Tuesday, March 1st. The stock was sold at an average price of $48.04, for a total transaction of $425,202.04. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Andrea Sabens sold 1,242 shares of the company’s stock in a transaction that occurred on Tuesday, January 18th. The stock was sold at an average price of $26.93, for a total transaction of $33,447.06. The disclosure for this sale can be found here. Insiders sold a total of 112,860 shares of company stock worth $5,630,110 in the last 90 days. Corporate insiders own 1.60% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. lifted its stake in Lantheus by 1.4% in the fourth quarter. BlackRock Inc. now owns 10,675,397 shares of the medical equipment provider’s stock worth $308,412,000 after acquiring an additional 143,451 shares during the period. Thrivent Financial for Lutherans increased its holdings in shares of Lantheus by 2.5% during the fourth quarter. Thrivent Financial for Lutherans now owns 3,051,631 shares of the medical equipment provider’s stock valued at $88,161,000 after acquiring an additional 73,133 shares in the last quarter. William Blair Investment Management LLC increased its holdings in shares of Lantheus by 46,886.5% during the third quarter. William Blair Investment Management LLC now owns 2,631,246 shares of the medical equipment provider’s stock valued at $67,570,000 after acquiring an additional 2,625,646 shares in the last quarter. Silvercrest Asset Management Group LLC increased its holdings in Lantheus by 8.5% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 2,166,085 shares of the medical equipment provider’s stock worth $62,073,000 after buying an additional 169,335 shares in the last quarter. Finally, Artisan Partners Limited Partnership increased its holdings in Lantheus by 1.3% in the 3rd quarter. Artisan Partners Limited Partnership now owns 2,156,216 shares of the medical equipment provider’s stock worth $55,372,000 after buying an additional 27,095 shares in the last quarter. Institutional investors and hedge funds own 95.27% of the company’s stock.
Lantheus Company Profile (Get Rating)
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.
- Get a free copy of the StockNews.com research report on Lantheus (LNTH)
- UiPath Stock is Nearing Rock Bottom Down Here
- Array Technologies Stock Giving Another Ground Floor Entry
- 3 Undervalued S&P 500 Stocks to Buy Now
- 3 Undervalued Easter Eggs to Watch For This Earnings Season
- Lululemon Rises On Wave Of Price Target Increases
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.